Glycogen storage disease type II natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{Glycogen storage disease type II}} {{CMG}} ==Overview== ==Natural History== ==Complications== ==Prognosis== The prognosis for individuals with Pompe disease va...") |
No edit summary |
||
Line 2: | Line 2: | ||
{{Glycogen storage disease type II}} | {{Glycogen storage disease type II}} | ||
{{CMG}} | {{CMG}} | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
==Overview== | ==Overview== | ||
==Natural History== | ==Natural History== | ||
Line 20: | Line 22: | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Inborn errors of metabolism]] | [[Category:Inborn errors of metabolism]] | ||
[[Category:Needs content]] |
Revision as of 02:23, 20 September 2012
Glycogen storage disease type II Microchapters |
Differentiating Glycogen storage disease type II from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type II natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type II natural history, complications and prognosis |
FDA on Glycogen storage disease type II natural history, complications and prognosis |
CDC on Glycogen storage disease type II natural history, complications and prognosis |
Glycogen storage disease type II natural history, complications and prognosis in the news |
Blogs on Glycogen storage disease type II natural history, complications and prognosis |
Directions to Hospitals Treating Glycogen storage disease type II |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Natural History
Complications
Prognosis
The prognosis for individuals with Pompe disease varies according to the onset and severity of symptoms. Without treatment the disease is particularly lethal in infants and young children.
Myozyme (alglucosidase alfa), a recombinant form of the human enzyme acid alpha-glucosidase, is currently being used to replace the missing enzyme. Myozyme helps break down glycogen. In a study[1] which included the largest cohort of patients with Pompe disease treated with enzyme replacement therapy (ERT) to date findings showed that Myozyme treatment clearly prolongs ventilator-free survival and overall survival in patients with infantile-onset Pompe disease as compared to an untreated historical control population. Furthermore, the study demonstrated that initiation of ERT prior to 6 months of age, which could be facilitated by newborn screening, shows great promise to reduce the mortality and disability associated with this devastating disorder.
The only "cure" for Glycogen Storage Disease Type II may ultimately lay in future technologies such as gene therapy.
References
- ↑ Wagner KR (2007). "Enzyme replacement for infantile Pompe disease: the first step toward a cure". Neurology. 68 (2): 88–9. doi:10.1212/01.wnl.0000253226.13795.40. PMID 17210887.